CureVac raises $105M to advance therapeutic cancer vaccines

09/19/2012 | BioWorld Online

Germany's CureVac secured $104.9 million in private equity financing from dievini Hopp BioTech Holding. The proceeds will help advance the development of CureVac's mRNA-based therapeutic prostate cancer vaccine, CV9103, and nonsmall-cell lung cancer vaccine, CV9201.

View Full Article in:

BioWorld Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA